Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ILK | Q13418 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078635 | 0.83 | ILK (0.33) | ACACBILKCACNA1B | |
| SCHEMBL15080296 | 0.82 | ILK (0.36) | ACACBILKMAPTRAB9AALDH1A1 | |
| SCHEMBL12617487 | 0.82 | SCN9A (0.41) | ACACB | |
| SCHEMBL12617493 | 0.81 | CACNA1B (0.36) | ACACBILKCACNA1B | |
| SCHEMBL12617515 | 0.80 | SLC6A4 (0.35) | ACACBILKALDH1A1KDM4E | |
| SCHEMBL20691501 | 0.79 | ACACB (0.35) | ACACBILKALDH1A1HPGDKDM4E | |
| SCHEMBL19410334 | 0.76 | LMNA (0.45) | MEN1MAPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL12617699 | 0.74 | ACACB (0.36) | ACACBILKMAPTALDH1A1CACNA1B | |
| SCHEMBL25338089 | 0.72 | LMNA (0.46) | MEN1MAPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1043362 | 0.71 | ALDH1A1 (0.36) | MEN1MAPTRAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932365-B2 | Protein labeling with cyanobenzothiazole conjugates | PROMEGA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170283456-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-10-05 | — | — | US | disclosed |
| US-9689868-B2 | Protein labeling with cyanobenzothiazole conjugates | PROMEGA CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2626703-B1 | Protein labeling with cyanobenzothiazole conjugates | PROMEGA CORP (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3141905-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | Promega Corporation (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170016888-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| EP-2269064-B1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | PROMEGA CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9459249-B2 | Protein labeling with cyanobenzothiazole conjugates | PROMEGA CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2626703-A1 | Protein labeling with cyanobenzothiazole conjugates | Promega Corporation (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2269064-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | Promega Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009142678-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | PROMEGA CORPORATIN (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090263843-A1 | Protein labeling with cyanobenzothiazole conjugates | PROMEGA CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263843-A1 | Protein labeling with cyanobenzothiazole conjugates | QPCTL, BCAT1, QPCT | ACACB 1244/4885ILK 1698/4885MEN1 3244/4885 |
| US-20170283456-A1 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES | QPCTL, BCAT1, QPCT | ACACB 1244/4885ILK 1698/4885MEN1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.